DK2791129T3 - Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) -acetic acid esters - Google Patents
Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) -acetic acid esters Download PDFInfo
- Publication number
- DK2791129T3 DK2791129T3 DK12805725.4T DK12805725T DK2791129T3 DK 2791129 T3 DK2791129 T3 DK 2791129T3 DK 12805725 T DK12805725 T DK 12805725T DK 2791129 T3 DK2791129 T3 DK 2791129T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- compound
- iii
- reaction
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201121557A GB201121557D0 (en) | 2011-12-15 | 2011-12-15 | Process |
PCT/GB2012/000903 WO2013088108A1 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2791129T3 true DK2791129T3 (en) | 2015-12-14 |
Family
ID=45560499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12805725.4T DK2791129T3 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) -acetic acid esters |
Country Status (28)
Country | Link |
---|---|
US (1) | US9102658B2 (zh) |
EP (1) | EP2791129B1 (zh) |
JP (2) | JP6300277B2 (zh) |
KR (1) | KR102018929B1 (zh) |
CN (1) | CN104114548B (zh) |
AU (1) | AU2012351341B2 (zh) |
BR (1) | BR112014014604B1 (zh) |
CA (1) | CA2859281C (zh) |
CY (1) | CY1117087T1 (zh) |
DK (1) | DK2791129T3 (zh) |
EA (1) | EA026617B1 (zh) |
ES (1) | ES2557762T3 (zh) |
GB (1) | GB201121557D0 (zh) |
HK (1) | HK1197671A1 (zh) |
HR (1) | HRP20151422T1 (zh) |
HU (1) | HUE028257T2 (zh) |
IL (1) | IL233132A (zh) |
ME (1) | ME02348B (zh) |
MX (1) | MX342273B (zh) |
PL (1) | PL2791129T3 (zh) |
PT (1) | PT2791129E (zh) |
RS (1) | RS54523B1 (zh) |
SG (1) | SG11201402798RA (zh) |
SI (1) | SI2791129T1 (zh) |
SM (1) | SMT201500327B (zh) |
UA (1) | UA111868C2 (zh) |
WO (1) | WO2013088108A1 (zh) |
ZA (1) | ZA201404246B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407820D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
WO2020136095A1 (en) | 2018-12-27 | 2020-07-02 | Chiesi Farmaceutici S.P.A. | Pharmaceutical composition comprising spherical agglomerates of timapiprant |
CN111978245A (zh) * | 2020-09-15 | 2020-11-24 | 上海毕得医药科技有限公司 | 一种3-氟-2-异丁基吡啶的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
US7188489B2 (en) | 2005-04-12 | 2007-03-13 | Martello Russell A | Portable air conditioner |
GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
US20110124683A1 (en) | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
RU2503672C2 (ru) | 2008-01-18 | 2014-01-10 | Оксаген Лимитед | Соединения, обладающие активностью антагонистов crth2 |
JP2011509990A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
AU2012351342A1 (en) | 2011-12-16 | 2014-07-24 | Atopix Therapeutics Limited | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
-
2011
- 2011-12-15 GB GB201121557A patent/GB201121557D0/en not_active Ceased
-
2012
- 2012-12-14 PT PT128057254T patent/PT2791129E/pt unknown
- 2012-12-14 MX MX2014007129A patent/MX342273B/es active IP Right Grant
- 2012-12-14 HU HUE12805725A patent/HUE028257T2/en unknown
- 2012-12-14 WO PCT/GB2012/000903 patent/WO2013088108A1/en active Application Filing
- 2012-12-14 JP JP2014546621A patent/JP6300277B2/ja not_active Expired - Fee Related
- 2012-12-14 KR KR1020147017740A patent/KR102018929B1/ko active IP Right Grant
- 2012-12-14 CN CN201280066207.8A patent/CN104114548B/zh not_active Expired - Fee Related
- 2012-12-14 ME MEP-2015-218A patent/ME02348B/me unknown
- 2012-12-14 US US14/364,509 patent/US9102658B2/en not_active Expired - Fee Related
- 2012-12-14 UA UAA201406835A patent/UA111868C2/uk unknown
- 2012-12-14 SI SI201230408T patent/SI2791129T1/sl unknown
- 2012-12-14 SG SG11201402798RA patent/SG11201402798RA/en unknown
- 2012-12-14 EA EA201490998A patent/EA026617B1/ru unknown
- 2012-12-14 ES ES12805725.4T patent/ES2557762T3/es active Active
- 2012-12-14 BR BR112014014604-7A patent/BR112014014604B1/pt not_active IP Right Cessation
- 2012-12-14 DK DK12805725.4T patent/DK2791129T3/en active
- 2012-12-14 RS RS20150871A patent/RS54523B1/en unknown
- 2012-12-14 CA CA2859281A patent/CA2859281C/en active Active
- 2012-12-14 PL PL12805725T patent/PL2791129T3/pl unknown
- 2012-12-14 EP EP12805725.4A patent/EP2791129B1/en active Active
- 2012-12-14 AU AU2012351341A patent/AU2012351341B2/en not_active Ceased
-
2014
- 2014-06-09 ZA ZA2014/04246A patent/ZA201404246B/en unknown
- 2014-06-15 IL IL233132A patent/IL233132A/en active IP Right Grant
- 2014-10-24 HK HK14110689.9A patent/HK1197671A1/zh not_active IP Right Cessation
-
2015
- 2015-12-23 SM SM201500327T patent/SMT201500327B/it unknown
- 2015-12-23 CY CY20151101189T patent/CY1117087T1/el unknown
- 2015-12-28 HR HRP20151422TT patent/HRP20151422T1/hr unknown
-
2017
- 2017-07-28 JP JP2017146700A patent/JP2018008985A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2791129T3 (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) -acetic acid esters | |
JP6133931B2 (ja) | メチル{4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]ピリミジン−5−イル}メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法 | |
JP5247728B2 (ja) | ベンズイミダゾール誘導体の製造方法 | |
KR20090079189A (ko) | Cmhtp 및 이의 중간체의 합성 방법 | |
WO2009010988A1 (en) | An improved, industrially viable process for the preparation of high purity paliperidone | |
JP6081450B2 (ja) | アセナピンの結晶塩 | |
JP2020524131A (ja) | 1,3−ベンゾジオキソール複素環式化合物の調製方法 | |
JP2015500325A5 (zh) | ||
WO2015124764A1 (en) | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate | |
WO2009121791A1 (en) | CONVERSION OF TRYPTOPHAN INTO ß-CARBOLINE DERIVATIVES | |
TW201623301A (zh) | 製備3-(3-(4-(1-胺基環丁基)苯基)-5-苯基-3H-咪唑並[4,5-b]吡啶-2-基)吡啶-2-胺之方法 | |
EP2202234A1 (en) | Purification of paliperidone | |
NZ626732B2 (en) | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters | |
WO2010082110A2 (en) | Novel process for preparing pure 6-fluoro-3-piperidin-4-yl-1,2-benzisoxazole hydrochloride and its conversion to paliperidone | |
CA3097628A1 (en) | Intermediates and processes for the preparation of linagliptin and its salts | |
AU2012324824B2 (en) | Processes for the preparation of 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and of its precursors | |
US7265238B2 (en) | Process for preparing methyl 4-(aminomethyl)benzoate | |
US20120071649A1 (en) | Process for the preparation of quetiapine fumarate |